Nephron Progenitor EVs for Stem Cell-Free Acute Kidney Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute kidney injury (AKI) are limited by high costs, infrastructure requirements, and challenges in delivering stem cells, and there is a need for a more effective and practical regenerative therapy.
Innovation Solution
Development of nephron progenitor extracellular vesicles (NP-EVs) produced by induced nephron progenitor cells, engineered to express SNAI2, EYA1, and SIX1, which are collected and purified for administration to treat AKI, potentially loaded with therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapy is used to treat acute kidney injury, then regenerative effect is improved, but cost and infrastructure requirements increase
Solution Approach 1:
The patent extracts the therapeutic function from whole stem cells and isolates it into extracellular vesicles (EVs). These EVs contain the beneficial microRNAs and proteins that mediate regenerative effects, while eliminating the need for complex stem cell cultivation infrastructure, patient-specific cell derivation, and sophisticated delivery systems. The EVs can be produced using simpler protocols and stored as off-the-shelf therapies.
Solution Approach 2:
The patent creates a functional copy of stem cell therapy using extracellular vesicles. Instead of using actual stem cells that require complex maintenance and differentiation protocols, the EVs serve as a simplified carrier that delivers the same therapeutic microRNAs and proteins. This copying approach maintains regenerative efficacy while dramatically reducing infrastructure and operational complexity.
2Reliability
If patient-specific stem cells are derived, then therapeutic efficacy is improved, but production time and cost increase
Solution Approach 1:
The patent segments the therapeutic function from the complex stem cell system. Rather than deriving and differentiating patient-specific stem cells through lengthy protocols, the approach isolates and purifies extracellular vesicles that naturally contain the therapeutic microRNAs and proteins. This segmentation allows for rapid production using standardized protocols, eliminating the time-consuming steps of cell derivation and differentiation while maintaining therapeutic efficacy.
Solution Approach 2:
The patent changes the fundamental parameter of the therapeutic product from live stem cells to extracellular vesicles. This parameter change enables the therapy to be produced using simpler, faster protocols that do not require maintaining living cells, differentiating them, or performing complex quality controls. The EVs can be produced in batches and stored, dramatically reducing production time compared to stem cell therapy.
3Reliability
If stem cells are administered, then regenerative potential is improved, but delivery challenges and immunogenicity increase
Solution Approach 1:
The patent uses extracellular vesicles as an intermediary carrier to deliver therapeutic microRNAs and proteins. These EVs serve as a natural delivery vehicle that avoids the immunogenicity issues associated with administering stem cells. The EVs can be engineered to target specific tissues, including the kidney, providing a controlled and safe delivery mechanism that simplifies administration while maintaining regenerative potential.
4Ease of manufacture
If off-the-shelf EV therapies are produced, then ease of production and storage are improved, but therapeutic customization is reduced
Solution Approach 1:
The patent develops a universal platform for producing extracellular vesicles that can be applied across different therapeutic scenarios. The standardized EV production protocol can generate vesicles loaded with various microRNAs and proteins depending on the donor cell type and conditioning media. This universality allows the same basic platform to create customized therapies for different indications, including acute kidney injury, chronic kidney disease, and other renal conditions, thereby maintaining adaptability while simplifying manufacturing.
Data Source
AI summary
Disclosed herein are nephron progenitor extracellular vesicles (EVs) that can be used to treat acute kidney injury and methods of using same. For example, disclosed herein is a composition involving nephron progenitor extracellular vesicles (EVs), wherein the EVs are produced by a method that involves: engineering donor cells to express exogenous SNAI2, EYA1, and SIX1, thereby producing induced nephron progenitor (iNP) cells, or obtaining nephron progenitor-like cells from less differentiated cell types including pluripotent stem cells such as induced pluripotent stem cells or embryonic stem cells; culturing the iNP or NPC cells in a culture medium, thereby producing a conditioned medium; and collecting and purifying nephron progenitor EVs from the conditioned medium.